Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Results
A total of 72 patients met the criteria for ultra-central tumor location. The PTV abutted the main bronchus, trachea or esophagus in 78%, 21% and 21% of cases, respectively. At a median follow-up of 19 months, 1- and 2-year local failure-free survival rates were 98% and 85%, respectively. Overall survival rates at 1 and 2 years were 77% and 52%, respectively. Grade 3 or higher toxicity was observed in 21%, of which 10 patients (14% of total) died of bronchopulmonary hemorrhage. A significant difference between patients with or without grade ≥3 toxicity was found for the mean dose (Dmean) to the main bronchus (p=0.015), where a Dmean BED of ≥90 Gy increased the risk of grade ≥3 toxicity significantly. Age, tumor histology and antithrombotic therapy was not significantly associated with the rate of grade ≥3 toxicity.

Conclusion
A protracted SBRT regimen of 60 Gy in 12 fractions for ultra-central lung tumors leads to high local control rates with acceptable toxicity in most patients, albeit at the risk of serious toxicity and even mortality. Therefore, possible risk factors of lung hemorrhage such as dose to the main bronchus, peri- or endobronchial tumor location and anti-vascular endothelial growth factor (anti-VEGF) or antithrombotic therapy should be taken into account. This study suggests to limit the Dmean(BED) to the main bronchus to 90 Gy.

PO-1173 Previous pneumectomy is a risk factor of severe radiation pneumonitis after IMRT for lung cancer
S. Tatsuno1, H. Doi1, W. Okada2, E. Inoue3, K. Nakamura4, K. Sano2, Y. Wada1, T. Uehara1, M. Inada1, K. Nakamatsu1, K. Monzen1, M. Hosono1, K. Matsumoto1, M. Tanooka2, M. Tanaka2, Y. Nishimura1
1Kindai University, Radiation Oncology, Osakasayama, Osaka, Japan; 2Takarazuka City Hospital, Radiotherapy, Takarazuka, Hyogo, Japan; 3Kindai University, Radiology, Osakasayama, Osaka, Japan

Purpose or Objective
Radiation therapy is a major treatment modality for management of locally advanced lung cancer. Volumetric modulate arc therapy (VMAT) and helical tomotherapy (HT) are current standard techniques of intensity modulated radiation therapy. However, risk factors of severe radiation pneumonitis (RP) are poorly understood in lung cancer patients who undergo VMAT and HT. The purpose of the present study was to assess risk factors of symptomatic RP in lung cancer patients who received IMRT using VMAT or HT.

Materials and Methods
Fifty-two patients who received definitive radiotherapy using VMAT or HT for lung cancer were included in this retrospective study. Twenty-nine and 23 patients received IMRT using VMAT and HT, respectively. Patients with distant metastasis or a follow-up duration of less than 90 days without grade 5 RP were excluded. Median age was 70 [range; 53-85]. One, five, and 46 patients had clinical stage 1B, stage 2AB, and stage 3ABC, respectively. Eight patients had past medical history of pneumectomy, and median residual lung volume was 2684 cc [range; 1723-3799]. Prescribed dose was a total of 60 Gy in 30 fractions. Clinical factors were tested for associations with symptomatic RP after radiotherapy. Time-to-event analyses were performed from the start of radiotherapy to the emergence of the event. Cumulative time to event was calculated using the Kaplan-Meier method. Potential factors associated with RP were evaluated using the COX proportional hazards model.

Results
The median follow-up time was 362 days [range; 77-927]. Eighteen and 8 patients experienced disease failure and died during the follow-up term, respectively. The median overall survival and disease-free survival time was 646 and 498 days, respectively. Twenty-four, 11, six, one, and one patients developed grade 1, 2, 3, 4, and 5 RP, respectively. The 6-month and 1-year incidence of grade ≥2 RP was 31.7 and 39.5%, respectively. Univariate analyses revealed that occurrence of grade ≥2 RP was significantly associated with planning target volume (PTV) ≥ 365 cc, whole lung volume receiving 20 Gy (V20) ≥ 18% and V5 ≥ 44%, the mean dose (Dmean) to the whole lung ≥ 11 Gy, V20 ≥ 36% and V5 ≥ 61% of ipsilateral lung and the use of VMAT (p = 0.018, 0.002, 0.001, 0.001, 0.002, 0.002, 0.042, respectively). However, no independent factors which were associated with grade ≥2 RP were observed in the multivariate analyses. In terms of grade ≥3 RP, univariate analyses revealed that past medical history of pneumectomy, whole lung volume ≤ 3150 cc, V5 ≥ 44% of whole lung, V20 ≥ 36% and V5 ≥ 61% of ipsilateral lung were significantly associated with the occurrence of RP. In addition, past medical history of pneumectomy was independently associated with grade ≥3 RP in the multivariate analyses (hazard rate, 4.888; 95% confidence interval, 1.028-23.239; p = 0.046).

Conclusion
Severe RP was associated with the previous pneumectomy in patients with lung cancer treated by VMAT or HT.

PO-1174 3-weekly paclitaxel-carboplatin with radiation for stage III NSCLC - option during COVID-19 pandemic
H. Wong1, F. Lim1, A. Cheng1
1Princess Margaret Hospital, Department of Oncology, Hong Kong, Hong Kong (SAR) China; 2Princess Margaret Hospital, Department of Oncology, Kwai Chung, Hong Kong (SAR) China; 3Princess Margaret Hospital, Department of Oncology, Kwai Chung, Hong Kong (SAR) China

Purpose or Objective
The optimal choice and schedule of chemotherapy (CT) given concurrently with radiation (RT) for primary treatment of stage III unresectable non-small cell lung cancer (NSCLC) remain debatable. 3-weekly paclitaxel-carboplatin (PC) is a convenient schedule but not well studied. This study aims to review the efficacy, toxicities and prognostic factors for treatment outcomes of this regime.

Materials and Methods
Patients with unresectable stage III (AJCC TNM 7th edition) NSCLC treated with radical chemoradiotherapy using 3-weekly PC (P 175mg/m2, C AUC=5 on day 1 of 21-day cycle) from January 2007 to April 2017 were
retrospectively reviewed. RT was given 5 days per week in 2 Gy daily fractions to the planning target volume using 3D-conformal technique. Total of 4 to 6 cycles of CT were allowed at clinicians’ discretion. Patients who had >2 CT cycles before RT, <1 cycle of CT concurrently with RT and total RT dose < 60 Gy were excluded.

**Results**

A total of 65 patients with median age 63 years (range 45-74 years) were included. Stage distribution was similar between IIIA (53.8%) and IIIB (46.2%). Majority (41.5%) of patients had adenocarcinoma, followed by squamous histology (38.5%). Most patients received 60 Gy of RT (96.9%) and 4 cycles of CT (83.1%). At a median follow-up of 29.5 months (mo) (Interquartile range 13.4-53.6 mo), the median overall survival (OS) was 35.0 mo (95% CI 17.5-52.4 mo) and the median progressive free survival (PFS) was 12.2 mo (95% CI 8.7-15.8 mo). The 1, 3 and 5-year OS rates were 76.9%, 48.3% and 29.7% respectively. Multivariate analyses showed that gross tumour volume (HR 1.005 [95% CI 1.002-1.008]; p<0.01), mean heart dose ≥ 5 Gy (HR 2.507 [95% CI 1.293-5.108]; p<0.01) and more than 4 cycles of CT given (HR 3.830 [95% CI 1.479-9.921]; p <0.01) were independent prognostic factors for worse OS, while ≥ grade 2 esophagitis was an independent prognostic factor for worse PFS (HR 2.563 [95% CI 1.031-6.370]; p=0.04). The maximum grade toxicity was grade 2 in 20 patients (41.5%), grade 3 in 27 patients (20.0%) and grade 4 in 5 patients (7.7%). No grade 5 events were observed. The most common grade 3 or 4 toxicity was neutropenia, which occurred in 9 (13.8%) and 5 (7.7%) patients respectively. Neutropenic fever was seen in 3 patients (4.6%). Grade 2 or above pneumonitis and esophagitis occurred in 5 (7.7%) and 9 (13.8%) patients respectively.

**Conclusion**

Radical chemoradiotherapy using 3-weekly PC for unresectable stage III NSCLC is well tolerated, with comparable outcomes to historical data and less hospital visits which is preferred during the COVID-19 pandemic. Prospective studies evaluating whether this regime in combination with more sophisticated RT techniques to lower the cardiac and esophageal doses could improve the survival outcomes and further enhance the therapeutic ratio in the era of consolidative durvalumab are warranted.